Our Pipeline

F I B R O S I S

IPF

RIPF

CKD

NASH

D E R M A T O L O G Y

HAIR LOSS (AGA)

C N S

ALZHEIMER'S

M E T A B O L I C

DIABETES (T2D)

V I R A L

Multi-target Antiviral

F I B R O S I S

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Idiopathic Pulmonary Fibrosis (IPF)

Radiation Induced Pulmonary Fibrosis (RIPF)

Chronic Kidney Disease (CKD)

Non-alcoholic steatohepatitis (NASH)

Androgenic Alopecia (AGA)

Alzheimer's Disease (AD)

Type 2 Diabetes (T2D)

COVID-19

D E R M A T O L O G Y

C N S

M E T A B O L I C

cosmerna.co

V I R A L

SAMiRNA™ platform technology

Delivery

Beyond the liver to the inflamed, adipogenic, neoplastic tissues

in organs via various RoA

Partnership

If you are interested in partnering with us for the clinical development and the commercialization of novel RNAi therapeutics using our proprietary SAMiRNA™ technology, please contact us at
collaborations@sirnagen.com or fill out a form below.

Our Pipeline

F I B R O S I S

D E R M A T O L O G Y

C N S

M E T A B O L I C

V I R A L

F I B R O S I S

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

D E R M A T O L O G Y

C N S

M E T A B O L I C

V I R A L

SAMiRNA™ platform technology

Partnership

Partnership Inquiries